Changing medicine for good

It’s an audacious mission—a quest to radically change the course of medicine. We’re aligning our investments in scientific research, manufacturing and most of all, people, to change the way cancer and other serious diseases are treated.

Learn More

Advanced Immunotherapies for Cancer Patients

Our investigational technology programs T cells to recognize and attack cancer cells. It’s a revolutionary approach for the treatment of cancer and other serious diseases.

Learn about CAR and TCR technologies

In the Pipeline

We have multiple product candidates in development for a variety of cancers, including Non-Hodgkin lymphoma (NHL), acute lymphoblastic leukemia (ALL), and chronic lymphocytic leukemia (CLL).

See an in-depth view of our current pipeline

Work at Juno

If you’re interested in a career that pushes the bounds of what is possible and work that has the potential to revolutionize medicine, then we would like to hear from you.

View open positions and learn about life at Juno

Patients come first

If you are interested in learning more about CAR T cell therapy and the potential treatment process, we break down the process for you and direct you to resources provided by the leading blood cancer advocacy organizations.

Visit our patients page

Recent News

May 23: Juno Therapeutics Appoints Jay Flatley to Board of Directors
May 17: Juno Therapeutics to Present Key Clinical Data Updates on JCAR017 and JCAR014 at the 2017 American Society of Clinical Oncology Annual Meeting

View all news and events

Juno on Twitter

Everything Juno Therapeutics
@JunoThera

TRANSCEND data presented at #ICML2017, high durable response reported: https://t.co/7g3qPs9tRZ

Follow us on Twitter

Investors

Juno Therapeutics, Inc. NASDAQ: JUNO is a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer.

Visit our IR site

Press

Read the latest announcements about our progress and our people, and request Juno media assets.

Visit our Press Room